miR-155 as a Biomarker in B-Cell Malignancies

Table 3

miR-155 as prognostic biomarker in diffuse large B-cell lymphoma (DLBCL), its expression in relation to GCB or nGCB/ABC subtyping, and direct relation to prognosis.

Cohort	Molecular subtype	Sample type	Initial miR selection	Method	Outcome			Ref
					Prognosis	Measure	Molecular subtype
90 DLBCL; (51/39)	21 GCB; 69 nGCB	FFPE	Previous research	RT-qPCR	↑ poor	RA, OR	↑ nGCB	[32]
	20 GCB; 34 nGCB	FFPE	Global screening	RT-qPCR			↑ nGCB	[46]
	32 GCB; 28 nGCB	FFPE	Global screening	Microarray			↑ nGCB	[33]
	9 GCB; 12 nGCB	FFPE	Previous research	RT-qPCR			NS	[47]
	85 GCB; 34 ABC	CS	Previous research	Microarray			↑ ABC	[89]
	17 GCB; 18 ABC	CS, FFPE	Global screening	RT-qPCR			↑ ABC	[34]
	11 GCB; 7 ABC	CS, FFPE	Previous research	ISH; RT-qPCR			↑ ABC	[48]
	9 GCB; 9 nGCB	FFPE	Previous research	ISH; Microarray			NS	[90]
	8 GCB; 15 nGCB	CS	Previous research	RT-qPCR			NS	[50]
54 DLBCL; (27/27)	32 GCB; 27 ABC	CS	Global screening	Microarray	↑ poor	EFS	↑ ABC	[39]
	4 GCB; 19 ABC	CS	Previous research	RT-qPCR			↑ ABC	[51]
129 DLBCL		CS	Previous research		NS	PFS, OS		[75]
24 ABC					↑ improved	PFS, OS
53 DLBCL	25 GCB; 25 nGCB	FFPE	Previous research	RT-qPCR	NS	EFS, OS	↑ nGCB	[36]
	14 GCB; 36 nGCB	FFPE	Previous research	RT-qPCR			NS	[49]
200 DLBCL; (121/79)		FFPE	Previous research		NS	PFS, OS		[52]

( / ) in column 1: number of patients with high and low miR-155 expression; numbers in column 2 indicate how many DLBCL patients included for miR-155 expression evaluation in each molecular subtype; subtype: GCB, germinal center B-cell-like; nGCB, non-GCB; ABC, activated B-cell-like. Sample type: FFPE, formalin-fixed paraffin-embedded tissue samples; CS, clinical samples. Method: RT-qPCR, reverse transcription quantitative PCR; ISH, in situ hybridization. Prognosis: ↑, increased expression; ↓, decreased expression; NS, not significant. Outcome measure: RA, response assessment; OR, overall response; EFS, event-free survival; PFS, progression-free survival; OS, overall survival. Ref: reference.